Thursday, February 04, 2021 2:55:10 AM
https://www.globenewswire.com/news-release/2020/12/07/2140379/0/en/Matinas-BioPharma-Files-Preliminary-Proxy-for-Special-Meeting-of-Stockholders.html
MTNB inside buyers will not vote to split their inside-purchased stock, without guaranteeing that their shares will not be affected. There is something very peculiar about this scenario. And it looks like MTNB is in on it. Why would MTNB have a special meeting-vote to split the stock after their inside buys? Did anyone hear anything about the meeting and the votes?
Or is it that the insiders plan to sell their shares before and for how much? Be careful. There’s something strange going on here. And since they are talking reverse split, with Market Maker manipulation, says the company doesn’t look good. So they need the Market Maker to play LIQUIDITY games at 6:05 AM for a $2.35 spike that’s at $1.25 a day later and not the same day. The $2.35 was Market Maker Money - - it had to be. So how can a split be needed, if MAT9001 and LNC are as good as they say. LNC, by concept, would be the first drug delivery system to cross the Blood Brain Barrier. LNC IS A DISRUPTIVE BREAK THROUGH. LNC CAN PUT PHARMACEUTICAL COMPANIES OUT OF BUSINESS. I BELIEVE THAT MTNB IS IN SOME SORT OF TROUBLE, BECAUSE OF LNC. AND I ALSO STRONGLY BELIEVE THAT BIG PHARMA IS BEHIND THIS. LNC WAS REVIEWED BY MULTIPLE BIG PHARMA COMPANIES. IF BIG PHARMA IS STILL CHECKING LNC OUT, THEN MTNB IS BEING THREATENED OR BLACKMAILED. I CAN ASSURE YOU THAT REMDISIVIR DOES NOT NEED LNC DELIVERY. REMDISIVIR WAS ADMINISTERED WITHOUT LNC. SOMETHING IS GOING ON HERE. I BELIEVE THAT MTNB IS IN SOME SORT OF TROUBLE WITH BIG PHARMA GOONS.
Recent MTNB News
- Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Matinas BioPharma Prices $10 Million Registered Direct Offering • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 03/27/2024 08:05:00 PM
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response • GlobeNewswire Inc. • 03/22/2024 01:15:00 PM
- Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards • GlobeNewswire Inc. • 03/22/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 01:05:14 PM
- Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 12:35:32 PM
- Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis • GlobeNewswire Inc. • 02/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 12:30:25 PM
- Matinas BioPharma to Present at Biotech Showcase 2024 • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 12:40:40 PM
- Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides • GlobeNewswire Inc. • 12/27/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 12:40:46 PM
- Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA • GlobeNewswire Inc. • 12/21/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2023 02:46:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2023 02:46:29 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM